You are here

  • Home
  • Archive
  • Volume 21, Issue 1
  • Longer dual antiplatelet therapy (DAPT) after percutaneous coronary intervention has higher anti-ischaemic efficacy than shorter DAPT but is associated with more frequent bleeding

Article Text

Article menu
Download PDFPDF
Therapeutics/Prevention
Systematic review with meta-analysis
Longer dual antiplatelet therapy (DAPT) after percutaneous coronary intervention has higher anti-ischaemic efficacy than shorter DAPT but is associated with more frequent bleeding
  1. Eliano P Navarese
  1. SIRIO 2 Systematic Investigation and Research on Interventions and Outcomes (SIRIO) MEDICINE Research Network and Heinrich-Heine-University, Düsseldorf, Germany
  1. Correspondence to : Dr Eliano P Navarese, Division of Cardiology, Pulmonology and Vascular Medicine, Department of Internal Medicine, Heinrich-Heine-University, Moorenstr. 48, Düsseldorf 40225, Germany; elianonavarese{at}gmail.com

http://dx.doi.org/10.1136/ebmed-2015-110284

Statistics from Altmetric.com

    Commentary on: Spencer FA, Prasad M, Vandvik PO, et al. Longer- versus shorter-duration dual-antiplatelet therapy after drug-eluting stent placement: a systematic review and meta-analysis. Ann Intern Med 2015;163:118–26.OpenUrlCrossRefPubMed

    Context

    Dual antiplatelet therapy (DAPT) with aspirin plus a P2Y12 receptor antagonist is recommended after drug eluting stent implantation (DES) for at least 12 months by the American College of Cardiology/American Heart Association1 and for 6–12 months by European guidelines. Recent randomised controlled trials (RCT) suggested comparable efficacy of short-term DAPT versus therapy of at least 12 months, raising the question of whether prolonged DAPT offers clinical benefit. However, concerns about DES have arisen regarding the propensity …

    View Full Text

    Footnotes

    • Competing interests None declared.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Copyright information:

    Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/